A carregar...
An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype
BACKGROUND: In our previous dose-escalation study, we uncovered the maximum tolerated dose (MTD) of weekly irinotecan was escalated to 80 mg/m(2) and 65 mg/m(2) for UDP glucuronosyltransferase family 1 member A1 (UGT1A1) *1*1 and *1*28 rectal cancer patients in neoadjuvant chemoradiotherapy (nCRT)....
Na minha lista:
| Publicado no: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6557009/ https://ncbi.nlm.nih.gov/pubmed/31217818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284819852293 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|